Header Logo

Connection

CHERYL WALKER to Administration, Oral

Back to Details
This is a "connection" page, showing publications CHERYL WALKER has written about Administration, Oral.
CHERYL WALKER
Connection Strength
0.017
Administration, Oral
  1. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010 Dec 01; 116(23):5415-9.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.